BiomX announced that its phage cocktail, BX004, has been granted Orphan Drug Designation by the United States Food and Drug Administration, for the treatment of chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with cystic fibrosis. As a reminder, in August 2023, the FDA granted BX004 Fast Track designation for the treatment of chronic pulmonary infections caused by P. aeruginosa bacterial strains in patients with CF.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PHGE:
- BiomX treatment of chronic pulmonary infection granted FDA orphan status
- BiomX files $150M mixed securities shelf
- BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
- BiomX announces results from Part 2 of the Phase 1b/2a trial of BX004
- BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
